Empagliflozin after Acute Myocardial Infarction

Among patients hospitalized for acute myocardial infarction and at risk for heart failure, empagliflozin did not lead to a significantly lower risk of a first heart-failure hospitalization or death from any cause than placebo.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-04, Vol.390 (16), p.1455-1466
Hauptverfasser:	Butler, Javed, Jones, W. Schuyler, Udell, Jacob A., Anker, Stefan D., Petrie, Mark C., Harrington, Josephine, Mattheus, Michaela, Zwiener, Isabella, Amir, Offer, Bahit, M. Cecilia, Bauersachs, Johann, Bayes-Genis, Antoni, Chen, Yundai, Chopra, Vijay K., Figtree, Gemma, Ge, Junbo, Goodman, Shaun G., Gotcheva, Nina, Goto, Shinya, Gasior, Tomasz, Jamal, Waheed, Januzzi, James L., Jeong, Myung Ho, Lopatin, Yuri, Lopes, Renato D., Merkely, Béla, Parikh, Puja B., Parkhomenko, Alexander, Ponikowski, Piotr, Rossello, Xavier, Schou, Morten, Simic, Dragan, Steg, P. Gabriel, Szachniewicz, Joanna, van der Meer, Peter, Vinereanu, Dragos, Zieroth, Shelley, Brueckmann, Martina, Sumin, Mikhail, Bhatt, Deepak L., Hernandez, Adrian F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antidiabetics Benzhydryl Compounds - adverse effects Benzhydryl Compounds - therapeutic use Cardiac arrhythmia Cardiology Cardiology General Cardiovascular disease Cardiovascular diseases Clinical Medicine Clinical Medicine General Congestive heart failure Coronary Disease Death Diabetes Diabetes mellitus (non-insulin dependent) Double-Blind Method Ejection fraction Female Follow-Up Studies Glucosides - adverse effects Glucosides - therapeutic use Heart attacks Heart Disease Risk Factors Heart Failure Heart Failure - etiology Heart Failure - mortality Heart Failure - prevention & control Hospital-Based Clinical Medicine Hospitalization Humans Kaplan-Meier Estimate Kidney diseases Male Middle Aged Myocardial Infarction Myocardial Infarction - complications Myocardial Infarction - drug therapy Myocardial Infarction - mortality Patients Peptides Placebos Pulmonary arteries Sodium-Glucose Transporter 2 Inhibitors - adverse effects Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Statistical analysis Treatment Outcome Vein & artery diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Among patients hospitalized for acute myocardial infarction and at risk for heart failure, empagliflozin did not lead to a significantly lower risk of a first heart-failure hospitalization or death from any cause than placebo.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2314051